





# Endothelial-cell specific Wnt inhibition: novel therapy for renal fibrosis

Julie Goodwin, MD

Associate Professor of Pediatrics (Nephrology)  
Yale University School of Medicine


# Prevalence of chronic kidney disease is increasing




CKD, chronic kidney disease; T2D, Type 2 diabetes

1. Jha V, et al. *Lancet* 2013;382:260–272; 2. World Kidney Day: Chronic Kidney Disease. 2015. Available at: <http://www.worldkidneyday.org/faqs/chronic-kidney-disease/>

Status Quo




Goal






# Wnt signaling in endothelial cells is a key mechanism contributing to chronic kidney disease





# Blockade of Wnt signaling improves diabetic renal fibrosis



**Reversal** of renal fibrosis by **50%**





**Prevention** of up to **75%** renal fibrosis

# Blockade of Wnt signaling improves non-diabetic renal fibrosis

UUO only

UUO only + Wnt inhibitor

Sirius Red



**Reversal** of renal fibrosis by **66%**



Target



Tool compound



High-throughput assay



Novel animal model



# My qualifications

- Practicing pediatric nephrologist
- Published 2 high impact papers showing the effect of Wnt inhibition on atherosclerosis and renal fibrosis (*JCI Insight, Nat Comm*)
- Filed 2 provisional patents:
  - LGK974 as therapy for dyslipidemia
  - LGK974 as therapy for renal fibrosis

## Next steps

---

Seeking 100K pilot award

---

Propose to screen for target compounds that inhibit Wnt in endothelial cells

---

Flexible, coachable and open to collaboration

---

In search of expertise in the business and development space to help move this therapeutic idea forward